|Reactivity||Human, Mouse, Rat|
|Calculated MW||11710 Da|
|Homology||Rat, mouse, dog, pig - identical.|
|Other Names||Potassium voltage-gated channel subfamily E member 3, MinK-related peptide 2, Minimum potassium ion channel-related peptide 2, Potassium channel subunit beta MiRP2, KCNE3|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)RSRKVDKRSDPYH, corresponding to amino acid residues 81-93 of human KCNE3 (Accession Q9Y6H6 ). Intracellular, C-terminal part.|
|Peptide Confirmation||Confirmed by mass-spectrography and amino acid analysis.|
|Application Details||Immunocytochemistry (IC): - Human colon carcinoma cell line HT29cl.19A (see Rapetti-Mauss, M. et al. (2013) in Product Citations). Immunohistochemistry (IH): - Mouse vomeronasal organ (VNO) (1:250) (see Hagendorf, S. et al. (2009) in Product Citations).|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.8 mg/ml.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
|Formulation||Lyophilized powder. Phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.025% NaN3.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
KCNE3 (or MiRP2) is a member of a family of proteins that regulate the activity of voltage-dependent K+ channels. The other members of the family are KCNE1 (IsK, MiNK), KCNE2 (MiRP1), KCNE4 (MiRP3) and KCNE5 (MiRP4). KCNE1 is the founding member of the family and was initially believed to form a K+ channel itself, but was latter recognized that it worked as a regulatory b subunit associated with the Kv7.1 (KCNQ1) a protein. KCNE3 was discovered based on its homology with KCNE1. The KCNE regulatory subunits are small proteins (14- 20 kD) with a type-1 integral membrane topology. It is believed that both the cytoplasmic C-terminus tail and the transmembrane domain are necessary for the interaction with the a subunits. The stoichiometry of the KCNE subunits with their partner a subunits in the native channels is not clear and ratios ranging from 2 to 14 KCNE subunits per 4 a subunits have been proposed. KCNE3 is relatively widely expressed in several tissues with prominent expression in the kidney and skeletal muscle. KCNE3 is quite promiscuous and associations with Kv7.1, Kv3.4, Kv7.4 (KCNQ4), Kv11.1 (HERG), Kv2.1 and Kv3.1b have been demonstrated. The best characterized interactions are with the former two proteins. KCNE3 interacts with Kv7.1 in epithelial cells of the gastrointestinal tract where it appears to be important for Na+ absorption. In skeletal muscle KCNE3 couples to Kv3.4 to regulate muscle function. Indeed, a mutation in KCNE3 (R83H) has been associated with an inherited form of periodic paralysis (Thyrotoxic hypokalemic periodic paralysis).
References 1. Abbott, G.W. et al. (1999) Cell 97, 175. 2. Schroeder, B.C. et al. (2000) Nature 403, 196. 3. Abbott, G.W. et al. (2001) Cell 104, 217. 4. Abbott, G.W. and Goldstein, S.A.N. (2001) Mol. Interv. 1, 95. 5. Li, Y. et al. (2006) Neuroscientist 12, 199.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.